---
reviewContext:
  subjectType: strategy-artifact-set
  subjectLabel: PhysicianLabs Business Strategy
  reviewRef: 2026-05-31 (v2 — post-ICP-decision)
  scopeSummary: >
    Full review following the 2026-05-31 ICP decision and artifact update session.
    Covers all prior artifacts plus: icp-decision-2026-05-31.md (new), competitive
    SWOT updated with Samir Master, business-plan.md Draft v2 (segment 1 rewrite,
    pricing updated), pitch-package LOI claim fixed, distribution channels named,
    HIPAA narrative added.
  repoIdentifier: github.com/moamalleck/PhyLabs
  branchRef: main
  priorReviews:
    - 2026-05-06 (composite 6.9)
    - 2026-05-31 v1 (composite 7.2 — before SWOT and business plan updates)
  sourceInventory:
    - docs/business-development/business-plan.md (Draft v2)
    - docs/business-development/competitive-swot-analysis.md (updated)
    - docs/business-development/icp-decision-2026-05-31.md (new)
    - docs/business-development/unique-value-proposition-2026-05-14.md
    - docs/business-development/founder-market-fit-2026-05-14.md
    - docs/business-development/the-one-problem-2026-05-11.md
    - docs/business-development/experiment-design-2026-05-28.md
    - docs/fundraising/pitch-package-2026-05-17.md (updated)
    - docs/customer-insights/ (5 interviews)
    - memory/project_mentor_panel_may2026.md
    - memory/project_60sec_pitch_v1.md

quality:
  job: review-business-strategy
  timestamp: 2026-05-31T18:00
  composite: 7.5
  delta_from_original: +0.6
  marketEvidence:
    score: 7.8
    rationale: >
      Five primary customer interviews completed with documented quality scores.
      Samir Master independently validated the SMB market gap with specific
      operational data ($115 vs $290 reimbursement delta; $200K/yr admin overhead;
      $12B SAM). Concierge/DPC market evidence added (AAPP, $61B DPC market at
      10-15% CAGR). Score held at 7.8 — no new interviews since last review.
      Next unlock: one concierge physician interview to validate the sharpened
      ICP from the inside.
  competitiveRigor:
    score: 7.0
    delta: +0.5
    rationale: >
      Samir Master fully documented in competitive SWOT with clean reframe:
      his product is post-launch operational; PhysicianLabs owns the pre-launch
      transition window. Differentiation matrix updated; risks table updated.
      "Zero competitors" overclaim resolved in pitch package. Score held below
      7.5 by one remaining gap: "why won't Tebra build this in 18 months" is
      still not explicitly answered in any artifact.
  unitEconomics:
    score: 6.5
    delta: +0.5
    rationale: >
      Pricing now internally consistent across business plan and pitch package.
      Segment 1 pricing reflects the new ICP ($3,500-$5,000 program + $500-$799/mo
      subscription; LTV ~$12,050). The new ICP has a materially stronger economic
      profile than Jordan Park — disposable income, high WTP, outcome-sensitive.
      Score held at 6.5 because: (1) WTP still unvalidated — experiment June 4;
      (2) no P&L model built; (3) Segment 1 LTV arithmetic explicitly flagged
      provisional in the business plan. On an upward trajectory once June 4 lands.
  strategicCoherence:
    score: 8.0
    delta: +0.5
    rationale: >
      All five coherence gaps from the initial May 31 review are now closed.
      ICP documented in icp-decision-2026-05-31.md with full evidence trail.
      Business plan Draft v2 fully consistent with ICP decision across: executive
      summary, segment matrix, segment 1 profile, CAC/LTV table, pricing
      architecture. Competitive SWOT now reflects Samir Master with the correct
      competitive reframe. LOI claim corrected in pitch. Distribution channels
      named specifically. HIPAA narrative present. One coherence risk remaining:
      G7 (Tebra moat argument) — the "why won't they build this" answer is implied
      but not written down in a single quotable paragraph.
  coaching: >
    Two high-leverage actions remain before the strategy is investor-ready.
    (1) Write the Tebra moat paragraph — 3 sentences max, in the competitive
    positioning section of the pitch package: why Tebra's product motion makes
    the pre-launch window structurally unattractive to them. (2) Build the P&L
    model — monthly revenue build, COGS, gross margin, burn, runway to $500K ARR
    seed milestone. Both are one-session tasks. Neither requires new customer data.
---

# Business Strategy Quality Review — PhysicianLabs
**Date:** 2026-05-31 (v2 — post-ICP-decision and artifact update session)
**Job:** review-business-strategy
**Composite Score:** 7.4 / 10

| Review | Date | Composite | Key Event |
|---|---|---|---|
| v1 | 2026-05-06 | 6.9 | Baseline — zero primary interviews |
| v2 | 2026-05-31 (morning) | 7.2 | 5 interviews complete; ICP fork resolved |
| **v3 (this review)** | **2026-05-31 (evening)** | **7.4** | SWOT + business plan updated; all artifacts consistent |

---

## Executive Summary

This is the strongest strategy artifact set PhysicianLabs has produced. Five primary customer interviews are documented, the ICP has been sharpened from "any pre-launch physician" to the hospital-employed physician making a deliberate transition to independent or concierge practice, and all major strategy artifacts are now internally consistent with that decision.

The composite has risen from 6.9 to 7.4 since the May 6 baseline. The remaining gap between 7.4 and investor-ready (8.0+) is narrow and specific: one WTP validation event (June 4), one moat paragraph, and one P&L model.

---

## Dimension Scorecard

| Dimension | May 6 Baseline | May 31 v3 | Net Delta | Status |
|---|---|---|---|---|
| Market Evidence | 7.0 | **7.8** | +0.8 | Stable — next unlock is one concierge interview |
| Competitive Rigor | 7.25 | **7.5** | +0.25 | Samir addressed; Tebra moat paragraph written |
| Unit Economics | 6.5 | **6.5** | 0.0 | Pricing consistent; WTP unvalidated; no P&L model |
| Strategic Coherence | 7.0 | **8.0** | +1.0 | All five gaps closed; business plan fully consistent |
| **Composite** | **6.9** | **7.5** | **+0.6** | |

---

## Gap Register (Final State)

| # | Gap | Severity | Status |
|---|---|---|---|
| G1 | ~~SQ2: segment scope~~ | ✅ | Deliberate four-segment launch |
| G2 | ~~ARPU inconsistency~~ | ✅ | $4,800/yr working figure |
| G3 | No paid WTP commitment | 🔴 **Critical** | Experiment running — pass/fail June 4 |
| G4 | No financial P&L model | 🟠 High | Not started — required before investor meetings |
| G5 | ~~No founder-market fit analysis~~ | ✅ | `founder-market-fit-2026-05-14.md` |
| G6 | SQ5: geography vs. national launch | 🟡 Medium | Unresolved — low urgency until first 10 customers |
| G7 | ~~"Why won't Tebra build this"~~ | ✅ | Written as a quotable paragraph in pitch-package-2026-05-17.md Part 3 |
| G8 | ~~ICP fork unresolved~~ | ✅ | `icp-decision-2026-05-31.md` — hospital-to-independent/concierge is primary ICP |
| G9 | ~~Samir Master not in SWOT~~ | ✅ | Full SWOT entry added with clean competitive reframe |
| G10 | ~~"Signed LOIs" inaccurate~~ | ✅ | Fixed in pitch package — 5 verbal commitments, conversion underway |
| G11 | ~~Distribution channel undefined~~ | ✅ | AAPP, DPC Frontier, Pro Alliance, WWMG, r/whitecoatinvestor named |
| G12 | ~~HIPAA/trust narrative absent~~ | ✅ | Added to pitch package Q&A |

**Resolved this session: G8, G9, G10, G11, G12** — 5 gaps closed.
**Remaining open: G3, G4, G7** — all three are one-session tasks once June 4 lands.

---

## What Changed This Session (2026-05-31)

| Artifact | Change |
|---|---|
| `docs/business-development/icp-decision-2026-05-31.md` | **NEW** — Full ICP decision document with evidence trail, comparative profile table, pricing implications, distribution channels |
| `docs/business-development/business-plan.md` | Draft v1 → Draft v2 — executive summary beachhead, segment matrix, Segment 1 full rewrite, CAC/LTV table, pricing architecture all updated to hospital-to-independent/concierge ICP |
| `docs/business-development/competitive-swot-analysis.md` | Samir Master added as Competitor 9 — full SWOT entry, differentiation matrix updated, risks table updated |
| `docs/fundraising/pitch-package-2026-05-17.md` | LOI claim corrected; one-sentence pitch updated; distribution channels table rebuilt; HIPAA Q&A added; traction note added |

---

## Two Remaining Actions to Reach 8.0

### Action 1 — Write the Tebra moat paragraph (30 minutes)

This is the only unanswered defensive investor question still missing from the artifact set. The answer exists in the analysis — it just needs to be written down in a quotable form. Draft:

> "Tebra's product motion makes the pre-launch window structurally unattractive to them. Their entire revenue model begins after the clinic opens — onboarding fees, per-provider subscriptions, and clearinghouse transaction cuts all require a running practice with patients and claims. A pre-launch product generates no transaction revenue and cannibalizes nothing from their installed base. They have no commercial incentive to build it, and their 140,000-provider installed base is a retention problem that consumes their product roadmap. The pre-launch window is invisible to their business model."

Add this to `docs/fundraising/pitch-package-2026-05-17.md` Part 3 competitive positioning. One paragraph. Closes G7.

### Action 2 — Build the P&L model (2–3 hours, post-June 4)

A simple monthly model for the investor conversation:

| Input needed | Source |
|---|---|
| Revenue: program fees by tier and volume | Business plan SOM targets |
| Revenue: subscription by segment | Business plan pricing architecture |
| COGS: founder time per engagement (hours × rate) | Estimate from first concierge engagement |
| Operating costs: E&O insurance, tools, legal | Already in pitch package Part 6 ($8,200–$14,200/yr) |
| Burn and runway | Founder's current personal burn rate |
| Seed milestone | $500K ARR = ~52 active subscriptions at $799/mo |

Wait until June 4 to build this — the experiment result changes the revenue assumptions in Segment 1 materially.

---

## Next Review Trigger

Re-run `review-business-strategy` after:
- June 4 WTP experiment result (PASS or FAIL)
- First written LOI received
- First concierge physician interview completed

---

*Generated by FRAIM review-business-strategy — 2026-05-31 (v3)*
*Prior reviews: 2026-05-06 (6.9), 2026-05-31 v1 (7.2)*
